P2RY12 and acute coronary syndrome: Based on large, multi-center randomized controlled trials (RCTs), guidelines recommend dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and a P2Y12 inhibitor for 12 months after an acute coronary syndrome (ACS), regardless of management strategy: medical management, percutaneous intervention (PCI), or coronary artery bypass grafting (CABG) [1–10].